Literature DB >> 16840828

A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism.

P Boudou1, F Ibrahim, C Cormier, E Sarfati, J C Souberbielle.   

Abstract

Since the demonstration that vitamin D status might influence the clinical and biological expression of primary hyperparathyroidism (PHPT), a serum 25-hydroxy vitamin D (25-OHD) concentration of 50 nmol/l has been considered by an expert panel as the minimum level to be maintained in asymptomatic PHPT patients. Two yr after this recommendation, we aimed to evaluate the frequency of serum 25-OHD concentrations below this threshold in PHPT patients. In the present study, serum 25-OHD, second- and third-generation PTH, calcium, phosphate, magnesium, albumin and creatinine were measured in 72 out 145 consecutive PHPT patients operated on in our Endocrine Surgery Department, in whom blood samples were available before as well as two days after surgical intervention. Before surgery, the frequency of serum 25-OHD levels <50 nmol/l ranged from 91.5 to 100% whatever the classification used to identify patients: whole group, symptomatic vs asymptomatic, patients with calcium levels >3 vs <3 mmol/l. 25-OHD concentrations correlated negatively with the weight of adenoma, PTH levels, and total calcium concentrations measured before surgery. Pre-operative PTH levels, whatever the assay used, and total calcium concentrations were positively and significantly correlated. Two days post-surgery, 13 patients were moderately hypocalcemic. Neither pre-surgery 25-OHD nor PTH, calcium or phosphorus level or adenoma weight were predictive of post-operative hypocalcemia. The dramatic frequency of low 25-OHD concentrations in our PHPT patients demonstrates that the above-mentioned recommendation is far from being applied in France despite evidence of worsening expression of PHPT with decreasing 25-OHD serum levels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16840828     DOI: 10.1007/BF03344140

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  19 in total

Review 1.  Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century.

Authors:  John P Bilezikian; John T Potts; Ghada El-Hajj Fuleihan; Michael Kleerekoper; Robert Neer; Munro Peacock; Jonas Rastad; Shonni J Silverberg; Robert Udelsman; Samuel A Wells
Journal:  J Bone Miner Res       Date:  2002-11       Impact factor: 6.741

2.  Technical and clinical characterization of the Bio-PTH (1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone.

Authors:  Masaaki Inaba; Kiyoshi Nakatsuka; Yasuo Imanishi; Masakazu Watanabe; Yuji Mamiya; Eiji Ishimura; Yoshiki Nishizawa
Journal:  Clin Chem       Date:  2003-12-18       Impact factor: 8.327

3.  A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.

Authors:  P Lips; T Duong; A Oleksik; D Black; S Cummings; D Cox; T Nickelsen
Journal:  J Clin Endocrinol Metab       Date:  2001-03       Impact factor: 5.958

4.  Vitamin-D deficiency and primary hyperparathyroidism.

Authors:  N J Woodhouse; F H Doyle; G F Joplin
Journal:  Lancet       Date:  1971-08-07       Impact factor: 79.321

5.  Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism.

Authors:  G A Lumb; S W Stanbury
Journal:  Am J Med       Date:  1974-06       Impact factor: 4.965

6.  Multifactorial risk profile for bone fractures in primary hyperparathyroidism.

Authors:  Erik Nordenström; Johan Westerdahl; Birger Lindergård; Pia Lindblom; Anders Bergenfelz
Journal:  World J Surg       Date:  2002-09-26       Impact factor: 3.352

7.  Risk factors for postoperative hypocalcemia after surgery for primary hyperparathyroidism.

Authors:  J Westerdahl; P Lindblom; S Valdemarsson; S Tibblin; A Bergenfelz
Journal:  Arch Surg       Date:  2000-02

8.  Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism.

Authors:  V Kantorovich; M A Gacad; L L Seeger; J S Adams
Journal:  J Clin Endocrinol Metab       Date:  2000-10       Impact factor: 5.958

9.  Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency.

Authors:  Andrew Grey; Jenny Lucas; Anne Horne; Greg Gamble; James S Davidson; Ian R Reid
Journal:  J Clin Endocrinol Metab       Date:  2005-01-11       Impact factor: 5.958

10.  Post-parathyroidectomy hypocalcemia: incidence, risk factors, and management.

Authors:  Elizabeth A Mittendorf; James I Merlino; Christopher R McHenry
Journal:  Am Surg       Date:  2004-02       Impact factor: 0.688

View more
  24 in total

1.  Pre-operative localization of abnormal parathyroid tissue by 99mTc-sestamibi in primary hyperparathyroidism using four-quadrant site analysis: an evaluation of the predictive value of vitamin D deficiency.

Authors:  Yu-Kwang Donovan Tay; Randy Yeh; Jennifer H Kuo; Catherine McManus; James A Lee; John P Bilezikian
Journal:  Endocrine       Date:  2018-02-05       Impact factor: 3.633

2.  Vitamin D and primary hyperparathyroidism: more insights into a complex relationship.

Authors:  Marcella D Walker; John P Bilezikian
Journal:  Endocrine       Date:  2016-11-17       Impact factor: 3.633

3.  Changes in bone turnover markers in primary hyperparathyroidism and response to surgery.

Authors:  P Rajeev; A Movseysan; A Baharani
Journal:  Ann R Coll Surg Engl       Date:  2017-09       Impact factor: 1.891

4.  Vitamin D in Primary Hyperparathyroidism: Effects on Clinical, Biochemical, and Densitometric Presentation.

Authors:  Marcella D Walker; Elaine Cong; James A Lee; Anna Kepley; Chiyuan Zhang; Donald J McMahon; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2015-06-16       Impact factor: 5.958

5.  Association between serum 25-hydroxyvitamin D level and subclinical cardiovascular disease in primary hyperparathyroidism.

Authors:  Marcella D Walker; Elaine Cong; Anna Kepley; Marco R Di Tullio; Tatjana Rundek; Shunichi Homma; James A Lee; Rui Liu; Polly Young; Chiyuan Zhang; Donald J McMahon; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2013-11-27       Impact factor: 5.958

6.  Effect of Low Vitamin D on Volumetric Bone Mineral Density, Bone Microarchitecture, and Stiffness in Primary Hyperparathyroidism.

Authors:  Marcella D Walker; Kyle K Nishiyama; Bin Zhou; Elaine Cong; Ji Wang; James A Lee; Anna Kepley; Chengchen Zhang; X Edward Guo; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2016-01-08       Impact factor: 5.958

Review 7.  Asymptomatic primary hyperparathyroidism.

Authors:  Shonni J Silverberg; Marcella D Walker; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

8.  Impact of vitamin D deficiency on the clinical and biochemical phenotype in women with sporadic primary hyperparathyroidism.

Authors:  Giuseppe Viccica; Filomena Cetani; Edda Vignali; Mario Miccoli; Claudio Marcocci
Journal:  Endocrine       Date:  2016-03-31       Impact factor: 3.633

Review 9.  Primary hyperparathyroidism.

Authors:  Marcella D Walker; Shonni J Silverberg
Journal:  Nat Rev Endocrinol       Date:  2017-09-08       Impact factor: 43.330

10.  Lower vitamin D levels in surgical hyperparathyroidism versus thyroid patients.

Authors:  Brenessa M Lindeman; Catherine E Pesce; Hua-Ling Tsai; Helina Somervell; Christopher B Umbricht; Jeanne Kowalski; Martha A Zeiger
Journal:  Am Surg       Date:  2014-05       Impact factor: 0.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.